secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIGAND PHARMACEUTICALS INC (LGND)
CIK:        0000886163
Form:       8-K
Filed at:   2026-09-24T11:15:07+00:00
Accession:  0000886163-26-000054
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ligand invests up to $47M in AvenCell for royalty on CAR-T pipeline
-------------------------------------------------------------------

- Ligand commits $41M for mid single-digit to low double-digit royalty on worldwide net sales of AvenCell pipeline assets, including AVC-201 and AVC-203.
- Funding in four tranches; first at closing, rest on clinical milestones and financing conditions.
- Ligand also commits up to $6M in AvenCell Series C financing.
- AvenCell's lead candidate AVC-201 is in Ph1b for relapsed/refractory AML; AVC-203 in Ph1a for B-cell malignancies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886163/000088616326000054/0000886163-26-000054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886163/000088616326000054/lgnd-20260924.htm
  HTML page:      https://secwatch.observer/filing/0000886163-26-000054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer